Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Videos

Inflammatory Oligodendrocyte Precursor Cells and Remyelination in MS
Videos
Inflammatory Oligodendrocyte Precursor Cells and Remyelination in MS
10/06/2020
In this video, Peter Calabresi, MD, discusses the findings from his award-winning study, which suggested that inhibiting immune activation of oligodendrocyte precursor cells may foster remyelination among patients with multiple sclerosis. Dr...
In this video, Peter Calabresi, MD, discusses the findings from his award-winning study, which suggested that inhibiting immune activation of oligodendrocyte precursor cells may foster remyelination among patients with multiple sclerosis. Dr...
In this video, Peter Calabresi,...
10/06/2020
Neurology
Managing MS During the Pandemic: DMTs, Telemedicine, and More
Videos
Managing MS During the Pandemic: DMTs, Telemedicine, and More
09/30/2020
In this video, Bardia Nourbakhsh, MAS, MD, gives an overview of how COVID-19 has changed how he and his colleagues see and treat patients with multiple sclerosis in their tertiary specialty care center, and the challenges that have arisen...
In this video, Bardia Nourbakhsh, MAS, MD, gives an overview of how COVID-19 has changed how he and his colleagues see and treat patients with multiple sclerosis in their tertiary specialty care center, and the challenges that have arisen...
In this video, Bardia...
09/30/2020
Neurology
Neuropsychiatric Disorders Among Patients With Multiple Sclerosis: Psychotropic Treatment Classes and Options
Videos
Neuropsychiatric Disorders Among Patients With Multiple Sclerosis: Psychotropic Treatment Classes and Options
09/18/2020
In this video, Laura T. Safar, MD, gives an overview of psychotropic treatment classes, their uses in the management of neuropsychiatric disorders among patients with multiple sclerosis, and important considerations for each class. She...
In this video, Laura T. Safar, MD, gives an overview of psychotropic treatment classes, their uses in the management of neuropsychiatric disorders among patients with multiple sclerosis, and important considerations for each class. She...
In this video, Laura T. Safar,...
09/18/2020
Neurology

Advertisement
Videos
Dawn Buse, PhD, on the OVERCOME Study
09/14/2020
In this video, Dr Buse discusses the findings of the OVERCOME Study, in which she and her colleagues investigated the influence of acute treatment optimization on disability and health-related quality of life among people with migraine.
In this video, Dr Buse discusses the findings of the OVERCOME Study, in which she and her colleagues investigated the influence of acute treatment optimization on disability and health-related quality of life among people with migraine.
In this video, Dr Buse discusses...
09/14/2020
Neurology
Neuropsychiatric Disorders Among Patients With Multiple Sclerosis: The Role of Psychotropics
Videos
Neuropsychiatric Disorders Among Patients With Multiple Sclerosis: The Role of Psychotropics
09/13/2020
In this video, Laura T. Safar, MD, discusses psychotropic treatment as one of several potential tools for the management of neuropsychiatric disorders among patients with multiple sclerosis.
In this video, Laura T. Safar, MD, discusses psychotropic treatment as one of several potential tools for the management of neuropsychiatric disorders among patients with multiple sclerosis.
In this video, Laura T. Safar,...
09/13/2020
Neurology
Videos
Urvish Patel, MD, on Status Migrainosus Triggers and Impact on Morbidity
09/09/2020
In this video, Dr Patel discusses the findings from his study on the the role of triggers in status migrainosus and its association with morbidity. This study was featured in the 2020 American Academy of Neurology Science Highlights.
In this video, Dr Patel discusses the findings from his study on the the role of triggers in status migrainosus and its association with morbidity. This study was featured in the 2020 American Academy of Neurology Science Highlights.
In this video, Dr Patel...
09/09/2020
Neurology

Advertisement

Key Takeaways from the PROMISE-2 Trial of Eptinezumab for Migraine
Videos
Key Takeaways from the PROMISE-2 Trial of Eptinezumab for Migraine
09/09/2020
In this video, Richard Lipton, MD, reviews key findings from the PROMISE-2 trial of eptinezumab for the treatment of chronic migraine.
In this video, Richard Lipton, MD, reviews key findings from the PROMISE-2 trial of eptinezumab for the treatment of chronic migraine.
In this video, Richard Lipton,...
09/09/2020
Neurology
Advantages of Intravenous Eptinezumab in the Treatment of Migraine
Videos
Advantages of Intravenous Eptinezumab in the Treatment of Migraine
09/09/2020
In this video, Richard Lipton, MD, discusses evidence of the effects of intravenous eptinezumab compared with other monoclonal antibodies that are FDA-approved for migraine.
In this video, Richard Lipton, MD, discusses evidence of the effects of intravenous eptinezumab compared with other monoclonal antibodies that are FDA-approved for migraine.
In this video, Richard Lipton,...
09/09/2020
Neurology
Important Research Advances in the Clinical Science of Concussion
Videos
Important Research Advances in the Clinical Science of Concussion
09/05/2020
In this video, Christina L. Master, MD, discusses recently published research on disparities in sports concussion when it comes to availability of flag football vs tackle football, the impact of active specialized sports medicine care vs a...
In this video, Christina L. Master, MD, discusses recently published research on disparities in sports concussion when it comes to availability of flag football vs tackle football, the impact of active specialized sports medicine care vs a...
In this video, Christina L....
09/05/2020
Neurology

Advertisement

Chronic Migraine: How Eptinezumab Affects Headache Impact Test-6 Scores
Videos
Chronic Migraine: How Eptinezumab Affects Headache Impact Test-6 Scores
08/28/2020
In this video, Richard Lipton, MD, discusses the results of the PROMISE-2 trial, including the observed reductions in Headache Impact Test-6 (HIT-6) total and item scores among patients with chronic migraine who were treated with eptinezumab.
In this video, Richard Lipton, MD, discusses the results of the PROMISE-2 trial, including the observed reductions in Headache Impact Test-6 (HIT-6) total and item scores among patients with chronic migraine who were treated with eptinezumab.
In this video, Richard Lipton,...
08/28/2020
Neurology

Advertisement

Advertisement

News

Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
News
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
11/01/2024
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug...
11/01/2024
Neurology
Gene therapy
News
Concerns Linger After Gene Therapy Shows Long-Term Benefit for Cerebral Adrenoleukodystrophy
10/28/2024
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel...
10/28/2024
Neurology
Patient with family
News
During Recovery, Stroke Patients Benefit from Supportive Social Networks
10/24/2024
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke. “In aging...
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke. “In aging...
Large networks of family and...
10/24/2024
Neurology
International Stroke Burden Saw Hike Over Last 30 Years
News
International Stroke Burden Saw Hike Over Last 30 Years
10/22/2024
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has...
10/22/2024
Neurology
Hands holding a head in profile with an illustrated heart over brain
News
Antiseizure Meds May Increase Cardiovascular Risk in Older Adults With Epilepsy
10/21/2024
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy...
10/21/2024
Neurology
FDA approval stamp
News
FDA Approves Infusion Treatment for Advanced Parkinson Disease in Adults
10/18/2024
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa...
10/18/2024
Neurology
Investigational Drug Improves Motor Function in Patients With SMA
News
Investigational Drug Improves Motor Function in Patients With SMA
10/16/2024
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational...
10/16/2024
Neurology
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
News
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
10/15/2024
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to...
10/15/2024
Neurology
An orange prescription container with generic pills spilling out in front of it
News
Masked Taper Plus CBT for Insomnia Effective in Benzodiazepine Discontinuation
10/10/2024
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined...
10/10/2024
Psych Congress Network

Advertisement

Advertisement

Alzheimer's Disease CME Series

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/12/2020
Neurology
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology
11/12/2020
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease...
11/12/2020
Neurology
Claim-Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early...
11/12/2020
Neurology
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
11/10/2020
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations...
11/10/2020
Neurology

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use